Cardiovascular Event Reduction and Adverse Events Among Subjects Attaining Low-Density Lipoprotein Cholesterol <50 mg/dl With Rosuvastatin: The JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) - HSIA, Judith; MACFADYEN, Jean G; MONYAK, John; RIDKER, Paul M (Journal of the American College of Cardiology, 2011)
Keywords: Age; Aged; Biological and medical sciences; Biomarkers - blood; Blood pressure; Body mass index; Cancer; Cardiology; Cardiology. Vascular system; Cardiovascular disease; Cardiovascular Diseases - drug therapy; Cardiovascular Diseases - enzymology; Cardiovascular Diseases - mortality; Cholesterol; Cholesterol, LDL - blood; Cohort Studies; Confidence intervals; Diabetes; Female; Fluorobenzenes - adverse effects; Fluorobenzenes - therapeutic use; Follow-Up Studies; Heart attacks; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use; Kinases; Lipoproteins; Male; Medical sciences; Middle Aged; Mortality; Pyrimidines - adverse effects; Pyrimidines - therapeutic use; Rosuvastatin Calcium; Stroke; Sulfonamides - adverse effects; Sulfonamides - therapeutic use; Human; Prevention; Reduction; Toxicity; Use; Secondary effect; Cholesterol LDL; Complication; Statin derivative; Rosuvastatin; Circulatory system; Cardiology